Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
← catalyst calendarNCT07219121 · readout ≤ 224 d
Sponsored by Travere Therapeutics, Inc. (industry) · TVTX — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-07 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Proteinuria
- Immunoglobulin A (IgA) Nephropathy
- Focal Segmental Glomerulosclerosis
- Kidney Transplant
Intervention
- Drug: Sparsentan
Primary outcome
what the primary-completion date above is the date OFUrinary protein/creatinine ratio (UPCR)
measured 36 weeks
Permalink · TVTX's whole pipeline · Catalyst calendar · Every registered study · What changed